T
Tarsus Pharmaceuticals, Inc. (TARS)
NMS – Real vaqt narxi. Valyuta: USD
59.41
-0.42 (-0.70%)
Bozor ochiq: May 13, 2026, 9:56 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
59.41
-0.42 (-0.70%)
Bozor ochiq: May 13, 2026, 9:56 AM EDT
Tarsus Pharmaceuticals, Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, Qo'shma Shtatlarda ko'z kasalliklari uchun terapevtik nomzodlarni ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya Demodex kana infestatsiyasi keltirib chiqaradigan demodex blefaritini davolash uchun lotilaner oftalmik eritmasi bo'lgan XDEMVY'ni taklif etadi. Kompaniya o'z mahsulotlarini maxsus dorixonalar va distribyutorlarga, shuningdek, klinikalarga, shifoxonalarga, dorixonalar va federal sog'liqni saqlash dasturlariga sotadi. Kompaniya, shuningdek, okulyar rosatsiyani davolash uchun 2-fazali klinik sinovlarda lotilanerning steril suvli jeli formulasi bo'lgan TP-04; va 2-fazali klinik sinovlarda Lyme kasalligining oldini olish uchun lotilanerning og'iz orqali qabul qilinadigan tabletka shakli bo'lgan TP-05, shuningdek, jamoat ichida bezgakni kamaytirish bo'yicha preklinik tadqiqotlarda. Bundan tashqari, u ko'z kasalliklari va yuqumli kasalliklarning oldini olishni o'z ichiga olgan inson tibbiyotida kasalliklarni davolash uchun lotilaner faol farmatsevtik ingredientini (API) ishlab chiqmoqda. Kompaniya Xitoyda Demodex blefariti va meibomian bezlari kasalliklarini davolash uchun TP-03ni ishlab chiqish va tijoratlashtirish bo'yicha Xi An Grand Chang An Pharmaceutical Co., Ltd. bilan ishlab chiqish va litsenziyalash shartnomasiga ega. Tarsus Pharmaceuticals, Inc. 2016 yilda tashkil etilgan va shtab-kvartirasi Kaliforniyaning Irvin shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Bobak R. Azamian M.D. | Co-Founder, President, CEO & Chairman |
| Dr. Bryan Wahl J.D., M.D. | General Counsel & Corporate Secretary |
| Dr. Seshadri Neervannan Ph.D. | Chief Operating Officer |
| Mr. Aziz Mottiwala M.B.A. | Chief Commercial Officer |
| Mr. David Nakasone | Head of Investor Relations |
| Mr. Jeffrey S. Farrow CPA | CFO & Chief Strategy Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-06 | 8-K | tars-20260506.htm |
| 2026-05-06 | 10-Q | tars-20260331.htm |
| 2026-04-28 | DEFA14A | tarsuspharmaceuticalsinc.htm |
| 2026-04-28 | DEF 14A | tars-20260428.htm |
| 2026-02-23 | 10-K | tars-20251231.htm |
| 2026-02-18 | 8-K | tars-20260218.htm |
| 2026-01-12 | 8-K | tars-20260112.htm |
| 2025-11-04 | 8-K | tars-20251104.htm |
| 2025-11-04 | 10-Q | tars-20250930.htm |
| 2025-08-06 | 8-K | tars-20250806.htm |
| Mr. Matthew Rossen M.B.A. | Vice President of Marketing |
| Mr. Scott Youmans | Vice President of Sales |
| Ms. Adrienne Kemp | Senior Director of Corporate Communications |
| Ms. Dianne C. Whitfield M.S.W. | Chief Human Resources Officer |